Prima to gain full ownership of its four subsidiaries
09 August, 2005 by Ruth BeranPrima Biomed (ASX:PRR) and the Austin Research Institute (ARI) have reached an in principle agreement enabling Prima to gain full ownership of its four subsidiary companies, Oncomab, Panvax, Cancer Vac and Arthron.
Progen to collaborate with Sanofi-Aventis on prostate cancer trials
09 August, 2005 by Ruth BeranBrisbane cancer drug developer Progen Industries (ASX:PGL, NASDAQ:PGLAF) will expand its phase II clinical trial program into prostate cancer to assess the efficacy and safety of its PI-88 angiogenesis inhibitor in combination with Sanofi-Aventis' chemotherapy agent Taxotere (docetaxel).
Bottom-line boost for LCT
09 August, 2005 by Graeme O'NeillA week after revealing spectacular preclinical results from its novel NeurotropinCell therapy for Huntington's disease, Auckland-based cell-therapy specialist Living Cell Technologies (ASX:LCT) has announced a therapeutic injection in its bottom line, after a successful capital raising pumped AUD$2.3 million into its coffers.
GTG sports gene test to be distributed in Japan
08 August, 2005 by Ruth BeranMelbourne-based Genetic Technologies (ASX:GTG) has signed an agreement with health and lifestyle industry supplier Sportsstyle for the marketing and distribution of its ACTN3 SportsGene Test throughout Japan.
Bio-Layer plans backdoor listing
08 August, 2005 by Ruth BeranBrisbane-based materials science specialist Bio-Layer is planning a backdoor listing on the ASX through SSH Medical (ASX:SSH) in September, aiming to raise between $3.5 and $5 million in capital to commercialise its products.
Alchemia named Queensland's 'smartest' company
05 August, 2005 by Helen SchullerBrisbane biopharma Alchemia (ASX:ACL) has been named the overall winner of the Queensland Government's Smart Awards 2005 for its efforts towards commercialising a new treatment to fight cancer.
Biosignal to raise $1m in placement
05 August, 2005 by Helen SchullerSydney-based Biosignal (ASX:BOS) has revealed plans to raise AUD$1 million for additional working capital, as it prepares to take its biofilm technology into contact lens clinical trials.
Melbourne Uni's 'nano-beacon' plays tricks with DNA
05 August, 2005 by Graeme O'NeillIn medicine, good things are coming in increasingly tiny packages: microscopic delivery systems made from polymers or other bio-friendly materials, and stuffed with therapeutic genes, proteins or small synthetic molecules, that can be implanted strategically in the brain or body.
Dispute between HeartWare and Ventracor heats up
04 August, 2005 by Helen SchullerThe legal battle between artificial heart firms HeartWare (ASX:HTW) and Ventracor (ASX:VCR) has intensified, with HeartWare filing a strong rebuttal to patent infringement action commenced against it by Ventracor and the University of Technology, Sydney.
Biotech to get Club fever
04 August, 2005 by Iain ScottJust what is the centre of the Australian biotech universe? Is it Melbourne, or Sydney, or Brisbane?
Genesis Biomedical reveals details of $1m rights issue
04 August, 2005 by Ruth BeranGenesis Biomedical (ASX:GBL) will be undertaking a non-renounceable rights issue to raise about AUD$1 million.
Circadian clocks up $21.8m profit
03 August, 2005 by Ruth BeranVeteran biotech investment group Circadian Technologies (ASX:CIR) has posted an AUD$21.77 million profit before tax for the 2004/05 financial year, up from $5.8 million for the previous corresponding year.
Norwood Immunology, US hospital team up for tolerance trial
03 August, 2005 by Ruth BeranMelbourne immune therapy developer Norwood Immunology (AIM:NIM) has signed a collaboration agreement with the Massachusetts General Hospital in Boston to conduct a proof-of-concept preclinical trial to determine whether tolerance to donated organ transplants can be established without the need for prolonged immunosuppressants.
LCT elated by Huntington's preclinical study
02 August, 2005 by Graeme O'NeillAuckland-based Living Cell Therapies (ASX:LCT) today announced "extraordinary" results from its preclinical trial of alginate-encapsulated pig brain cells in a primate model of Huntington's disease.
BresaGen signs two new contracts
02 August, 2005 by Helen SchullerAdelaide-based BresaGen (ASX:BGN) has signed two new contracts under its protEcol Services business unit.
